Clinical Trial Update: A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer [Phase 3]

View source ↗

Summary

Phase III study evaluating BD0801 in combination with chemotherapy for recurrent, platinum-resistant epithelial ovarian cancer has completed; results are not pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• BD0801

Snippet

Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. | Conditions: Ovarian Cancer | Phase 3 | Status: COMPLETED